<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479814</url>
  </required_header>
  <id_info>
    <org_study_id>AIDA-RE-1</org_study_id>
    <nct_id>NCT03479814</nct_id>
  </id_info>
  <brief_title>Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)</brief_title>
  <official_title>AIDA-RE-1: Adaptive Individualized Hig-Dose Radiotherapy Analysis-Rectum-1. Interventional Study on Neoadjuvant Adaptive-treatment of High Risk Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate achievement of complete pathologic response (pCR) in
      high-risk rectal cancer treated with neoadjuvant concomitant chemotherapy plus
      adaptive-intensity modulated imaging-guided radiotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIDA-RE-1 is an interventional prospective trial for the treatment of locally advanced
      high-risk rectal cancer. In neoadjuvant setting, patients are treated with standard
      chemotherapy plus experimental radiotherapy. The total dose to clinical target volume (CTV,
      rectum and locoregional lymph nodes) is 45 Gy, with a concomitant boost of 5 Gy to gross
      tumor volume (GTV), delivered with IMRT-SIB (intensity modulated radiotherapy-simultaneous
      integrated boost) technique in 25 fractions. After 2 weeks of treatment, patients are
      evaluated with 18 FDG-PET and sequential boost of 5 Gy (in 2 fractions) is planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete pathological response (pCR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>pCR is defined as ypT0N0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Acute toxicity is evaluated using CTCAE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>1 year</time_frame>
    <description>QoL is evaluated using EORTC QoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Late toxicity is evaluated using CTCAE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetric advantage of GTV-boost reduction</measure>
    <time_frame>6 weeks</time_frame>
    <description>Dosimetric advantage is evaluated using DVHs (Dose Volume Histograms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of PET-response as predictive factor</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation between SUV (Standardized Uptake Value) and pathological response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Radiotherapy</condition>
  <condition>Neoadjuvant Treatment</condition>
  <arm_group>
    <arm_group_label>IMRT-SIB plus sequential IG-RT boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT-SIB plus sequential IG-RT boost</intervention_name>
    <arm_group_label>IMRT-SIB plus sequential IG-RT boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of locally advanced rectal cancer (cT3N+, cT4Nx,
             local relapse, cT3N0); cT2N+ is acceptable if low rectum is involved

          -  M0

          -  ECOG 0-2

        Exclusion Criteria:

          -  M1

          -  familial adenomatous polyposis (FAP), non-polyposis hereditary colorectal cancer,
             inflammatory bowel disease

          -  severe cardiopathy

          -  previous pelvic RT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessio G Morganti, MD</last_name>
    <phone>0512143564</phone>
    <phone_ext>+39</phone_ext>
    <email>alessio.morganti2@unibo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessio G Morganti, MD</last_name>
      <phone>0512143564</phone>
      <phone_ext>+39</phone_ext>
      <email>alessio.morganti2@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant chemoradiation</keyword>
  <keyword>IMRT-SIB</keyword>
  <keyword>adaptive radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

